Evidence map›Paper›PMID 35039796›Full record

ArticleBMJ open ophthalmology2022

Persistent reduction of retinal microvascular vessel density in patients with moderate and severe COVID-19 disease.

Sandra Banderas García, David Aragón, Brahim Azarfane, Fernando Trejo, Xavier Garrell-Salat, Adrián Sánchez-Montalvá, Susana Otero-Romero, Jose Garcia-Arumi, Miguel Angel Zapata

Open access · goldAbstract read
In one paragraph

Article in BMJ open ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Sandra Banderas GarcíaDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain sandrabanderasgarcia@gmail.com.ORCID http://orcid.org/0000-0002-3641-3806
David AragónDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Brahim AzarfaneDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Fernando TrejoDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Xavier Garrell-SalatDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Adrián Sánchez-MontalváInfectious Diseases Department, Universitat Autònoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Susana Otero-RomeroPreventive Medicine and Epidemiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jose Garcia-ArumiDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Miguel Angel ZapataDepartment of Ophthalmology, Vall d'Hebron University Hospital, Barcelona, Catalunya, Spain.
Hebron University · PSGeneral Department of Preventive Medicine · VNUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to analyse the possible recovery or worsening in retinal microvasculature after 8 months in a previously studied COVID-19 cohort. METHODS AND ANALYSIS: A cross-sectional case-control study and a prospective longitudinal cohort study. Participants were the subjects of our previous study who re-enrolled for a new examination including a fundus photograph (retinography), an optical coherence tomography (OCT) scan and an OCT angiography. COVID-19 diagnosed patients were divided into three groups: group 1: mild disease, asymptomatic/paucisymptomatic subjects who received outpatient care; group 2: moderate disease and group 3: severe disease, both of which required hospital admission because of pneumonia. Statistical analyses were performed using SPSS software (V.23.0). Cross-sectional intergroup differences were analysed by means of analysis of variance for normally distributed variables and the Kruskal-Wallis test for non-normally distributed ones. In reference to the prospective part of the study (intragroup differences, baseline with 8-month comparison), a paired t-test was used for normally distributed data and Wilcoxon signed ranks sum for non-normally distributed data.

resultsThe fovea-centered superficial and deep vascular densities were significantly diminished in severe cases compared with mild cases (p=0.004; p=0.003, respectively, for superficial and deep) and to controls (p=0.014; p=0.010), also in moderate cases to mild group (p=0.004; p=0.003) and to controls (p=0.012; p=0.024). In the longitudinal study, no significant statistical differences were found between baseline and 8-month follow-up vessel density values.

conclusionWe demonstrated persistent reduction in the central vascular area over time in patients with moderate and severe COVID-19.

Indexed as

COVID-19Case-Control StudiesCross-Sectional StudiesFluorescein AngiographyHumansLongitudinal StudiesProspective StudiesTomography, Optical CoherenceCOVID-19imagingmacularetina

Identifiers

PMID35039796
PMCPMC8753095
OpenAlexW4205532379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.